In primary neonatal rat ventricular cardiomyocytes, dexrazoxane pretreatment reduced anthracycline-induced LDH release at responsive concentrations but did not significantly protect against hydrogen-peroxide injury. The response was not consistently dose-dependent. The tested dexrazoxane salt form was not specified. [2]
Dexrazoxane inhibited HL-60 proliferation with a reported 72-h IC50 of 25 μM. Anthracycline combinations were generally synergistic, but pre-incubation before daunorubicin weakened synergy and yielded additive or moderately antagonistic interactions at the highest equipotent concentrations. Anticancer compatibility therefore depends on the model, concentration ratio and schedule. [2]
Top2b depletion and doxorubicin-associated DNA-damage signalling in differentiated H9C2 cells
Cell-based study · Differentiated rat H9C2 cardiomyoblast-derived cells [1]
Dexrazoxane depleted Top2b and reduced doxorubicin-induced γ-H2AX accumulation. ICRF-161 did neither; ICRF-193 depleted Top2b. These are protein/signalling endpoints and support an association with topoisomerase II biology, rather than a direct cardiac-function measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM dexrazoxane; 1 μM doxorubicin for the DNA-damage comparison
- Exposure duration
- 24 h
- Method
- Cell treatment; Western blots for Top2 isoforms and γ-H2AX with tubulin loading controls
- Co-treatment
- Doxorubicin co-treatment in Figure 2D; analogues are separate comparators
- Reported limits
- Vehicle not specified for this cellular experiment. No numerical depletion percentage or IC50 is extracted.
Methods and source locations
Compound reported in the paper: Dexrazoxane; Compound label in the paper: DRZ (ICRF-187)
Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.
Figure 2B–D; Results: DRZ depletes cardiac TOP2B protein both in vitro and vivo; Methods: Drugs and antibodies, Cell culture, Western blot
Anthracycline versus hydrogen-peroxide injury in primary cardiomyocytes
Cell-based study · Primary neonatal ventricular cardiomyocytes isolated from 2-day-old Wistar rats [2]
Dexrazoxane pretreatment reduced anthracycline-induced LDH release at responsive concentrations, but showed no significant protection from hydrogen-peroxide injury. Protection was not consistently greater at 1000 μM than at lower dexrazoxane concentrations.
Literature-Reported Treatment Conditions
- Treatment concentration
- Dexrazoxane 10, 100 or 1000 μM; daunorubicin or doxorubicin 0.6–2.0 μM; H2O2 200, 300 or 500 μM
- Exposure duration
- Dexrazoxane pretreatment 3 h; anthracycline co-incubation 3 h followed by 48 h anthracycline-free period; H2O2 comparison 48 h
- Method
- LDH release expressed as percentage of total cellular LDH
- Vehicle
- DMSO; drug-free DMSO control
- Co-treatment
- Separate daunorubicin, doxorubicin or H2O2 injury comparisons
- Reported limits
- No exact bar-height values or IC50 inferred; final DMSO percentage not specified in the read methods.
Methods and source locations
Compound reported in the paper: Dexrazoxane; Compound label in the paper: DEX (ICRF-187)
Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.
Figure 2A–C and caption; Methods 1–2, 8; Results 1
Schedule-dependent interactions with anthracyclines in HL-60 cells
Cell-based study · Human HL-60 promyelocytic leukemia cell line [2]
Dexrazoxane had a reported 72-h antiproliferative IC50 of 25 μM. Simultaneous combinations with daunorubicin or doxorubicin were generally synergistic. Dexrazoxane pre-incubation before daunorubicin weakened synergy, with additive or moderately antagonistic behaviour at the highest equipotent concentrations. These observations do not establish preservation of anticancer efficacy in other models.
Literature-Reported Treatment Conditions
- Treatment concentration
- Single-agent IC50 reported as 25 μM; combination series at 1/8, 1/4, 1/2, 1, 2 and 4 times individual IC50 values, and separate 1:20 daunorubicin:dexrazoxane ratio
- Exposure duration
- 72-h co-incubation; additional dexrazoxane pre-incubation for 3 or 6 h; fixed-ratio comparison with 0 or 3 h pre-incubation
- Method
- MTT assay; Chou–Talalay combination analysis and simulated fraction-affected/combination-index curves
- Vehicle
- DMSO
- Co-treatment
- Daunorubicin or doxorubicin; qualitative interactions only
- Reported limits
- Table S1 not retrieved as usable original table; exact CI values, their variability and pair-specific values are not extracted. Figure 4 curves are simulations, not raw observations.
Methods and source locations
Compound reported in the paper: Dexrazoxane; Compound label in the paper: DEX (ICRF-187)
Dexrazoxane active-compound evidence only. The tested preparation is not verified as A10300 hydrochloride or an Adooq lot; retain the paper’s units without salt conversion.
Methods 1, 3, 8; Results 2; Figure 4A and caption; Discussion combination-schedule paragraph
50% proliferation decrease relative to untreated cells after single-agent dexrazoxane exposure: 72-h MTT proliferation assay; CalcuSyn median-effect analysis — Results 2: Proliferation studies, first paragraph; Methods 3 and 8